DRMA Dermata Corp: Price-to-Projected Revenue Ratio

Corporate company logo of Dermata Therapeutics Inc (DRMA)

Automated formula screening and AI skin modeling minimize routine tasks, impacting the projected P/S of Dermata Therapeutics (DRMA), where the 43.70 metric determines this level. Physician confidence in non-steroidal treatments strengthens the brand image. Anticipation of final test results for rosacea drugs will act as a growth catalyst, as current R&D expenditures are already priced into the asset value.

DRMA dermatarx.com: Forward Price-to-Revenue Multiple in the range 11/12/2026 - 11/14/2026

Analytical breakdowns for Dermata Corp (DRMA)

- current price and projected stock value:
Stock Price Dermata Therapeutics, Inc.|DRMA - Average Forecast Price
- company stock capitalization data:
Market Value Dermata Corp|DRMA - Value Adjusted for Debt and Cash
- book value of equity indicators:
Net Assets per Single Share Dermata Therapeutics|DRMA - Company Net Assets|Market Capitalization to Book Value Ratio dermatarx.com|DRMA - Company Total Assets
- debt and solvency information:
Total Debt to Equity Ratio Dermata Therapeutics|DRMA - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Dermata Therapeutics|DRMA - Company Aggregate Debts|Debt to Book Value Dermata Corp|DRMA - Company Long-Term Loans and Borrowings|Company Current Liabilities Dermata Therapeutics|Quick Ratio dermatarx.com
- business earnings and investment ratios data:
DRMA - Final Profit|Projected Future Earnings Dermata Therapeutics|DRMA - Market Cap to Earnings|Future Price to Earnings Dermata|DRMA - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Dermata Corp|DRMA - Operating profit EBITDA|Earnings per share for the last twelve months Dermata Therapeutics|DRMA - Earnings per one share for the last 12 months|Quarterly EPS earnings growth dermatarx.com|DRMA - Earnings per share growth rate in current year|Expected earnings per share growth for next year Dermata Therapeutics
- sales and revenue data:
DRMA - Revenue and Sales Volume|Company Future Sales Volume Dermata Therapeutics, Inc.|DRMA - Market Cap to Sales Volume|Forward P/S Multiple Dermata Corp
Fundamental company analysis:Dermata Therapeutics, Inc. (DRMA)
Manufactured products of Dermata Corp

Forward P/S is defined as the ratio of the current share price to the expected revenue per share, allowing for the assessment of the company's market value relative to its projected cash flows. The trend of the forward P/S indicator reflects the sensitivity of Dermata Therapeutics (DRMA) capitalization to the success of acne and rosacea therapy development in collaboration with clinics, signaling a revaluation of the potential for innovative substance delivery.

Key competitors

Forward P/S Multiple KRYS (Krystal Biotech)|Apogee Therapeutics Inc (APGE) - Market Cap to Future Revenue Ratio|ARQT - Price-to-Projected Revenue Ratio|Forward Price to Sales VCEL (Vericel Inc.)|Oruka Therapeutics Inc (ORKA) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Sanara MedTech|DBVT (DBV Tech) - Forward P/S Multiple|Forward P/S Multiple Solesence Inc.|Forward Price-to-Revenue Multiple DERM (Journey Medical)|Price to Expected Revenue Ratio FBRX|Forward P/S Multiple EMPG (Empro Group Inc)|Forward P/S Multiple sol-gel.com SLGL|AXIL: Forward Price-to-Revenue Multiple|Forward Price to Sales MDCX (Medicus Pharma Ltd)|VRCA (verrica.com) - Forward Price-to-Revenue Multiple|HOTH: Price to Expected Revenue Ratio|BFRI (Biofrontera, Inc.) - Forward P/S Multiple|VYNE: Forward Price to Sales|Forward P/S Multiple SNOA|QNRX - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Azitra Corp AZTR|Forward Price to Sales ELAB|Revance Therapeutics - Forward P/S Multiple